Molecule of the month. The 'skinny' on CB1 antagonists/inverse agonists: controversial obesity drugs will not go to FDA for approval

Curr Top Med Chem. 2008;8(17):1553. doi: 10.2174/156802608786413500.
No abstract available

MeSH terms

  • Animals
  • Anti-Obesity Agents / adverse effects*
  • Anti-Obesity Agents / chemistry
  • Anti-Obesity Agents / therapeutic use
  • Drug Approval
  • Drug Inverse Agonism
  • Humans
  • Obesity / drug therapy*
  • Receptor, Cannabinoid, CB1 / antagonists & inhibitors*
  • Receptor, Cannabinoid, CB1 / chemistry
  • United States
  • United States Food and Drug Administration

Substances

  • Anti-Obesity Agents
  • Receptor, Cannabinoid, CB1